Core Insights - The long-term efficacy and safety data from the ATTRibute-CM open-label extension trial demonstrate sustained clinical benefits of acoramidis in patients with ATTR-CM through Month 54, including significant reductions in all-cause and cardiovascular mortality [1][2][3] Efficacy and Safety Data - Acoramidis treatment resulted in a 44.7% reduction in all-cause mortality (ACM) and a 49.3% reduction in cardiovascular mortality (CVM) compared to placebo, marking the earliest timepoint in an open-label extension with such risk reduction [1][3] - The treatment mitigated the rise in NT-proBNP levels through Month 54, an effect not previously observed with disease-modifying treatments [1][3] - Continuous acoramidis treatment maintained heart failure-related quality of life scores (KCCQ-OS), indicating sustained improvements in both duration and quality of life for patients with ATTR-CM [1][3] Treatment Patterns and Patient Preferences - A real-world survey indicated that over half of physicians were not fully satisfied with current treatment options for ATTR-CM, and more than one-third of patients did not receive any treatment [4] - Patients expressed a preference for oral therapy, highlighting unmet treatment needs and the importance of shared decision-making in therapy selection [4] Regulatory Approvals - Acoramidis is approved as Attruby by the U.S. FDA and as BEYONTTRA by various European and Japanese regulatory agencies, with all labels specifying near-complete stabilization of TTR [4]

Core Insights - BridgeBio Pharma's Phase 3 clinical trial of acoramidis demonstrated a 59.1% risk reduction in all-cause mortality (ACM) or first cardiovascular hospitalization (CVH) in patients with hereditary transthyretin amyloidosis (ATTRv-CM) compared to placebo, supporting the hypothesis that stabilizing TTR may delay or prevent the disease [1][5] Group 1: Clinical Trials and Studies - The ACT-EARLY study is a randomized, double-blind, placebo-controlled trial enrolling approximately 600 asymptomatic carriers of a pathogenic TTR variant, aiming to evaluate the primary analysis of ATTRv disease diagnosis [1][3] - Acoramidis, a near-complete TTR stabilizer, is being tested in the ACT-EARLY study to determine if prophylactic treatment can delay or prevent the onset of variant ATTR [3][4] - The primary efficacy endpoint of the ACT-EARLY study is the time to development of ATTR-CM and/or ATTR-PN, with additional endpoints including safety, tolerability, and effects on cardiac imaging parameters [3] Group 2: Regulatory Approvals and Market Position - Acoramidis is approved as Attruby™ by the U.S. FDA and as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency, all indicating near-complete stabilization of TTR [1][6] - Current therapies for ATTR amyloidosis are only approved for treating diagnosed disease and do not provide prevention options for asymptomatic carriers, highlighting a significant unmet need in the market [4][6] Group 3: Industry Impact and Future Directions - The launch of the ACT-EARLY study reflects BridgeBio's commitment to advancing the genetic understanding of ATTR variants and improving patient care globally [2] - The study aims to establish a new prevention paradigm for asymptomatic carriers of genetic variants, potentially leading to earlier intervention and better clinical outcomes [2][4]